> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-48/
- Published: 2021-07-25T12:00:00.000Z
- Updated: 2026-09-14T17:07:38.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5149787

**Covid Emergency Use Authorizations Listing Update**  
7/23/2021 *Federal Register* notice: FDA has updated its listing of emergency use authorizations granted during the Covid-19 public health emergency. Each listing contains, among other things, conditions on the product’s emergency use. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-07-23/pdf/2021-15680.pdf?ref=fdaweb.com).

**Covid-19 Guidance Listing Updated**  
7/23/2021 *Federal Register* notice: FDA has updated its listing of guidance documents related to the Covid-19 public health emergency. The guidances have been implemented without prior comment, but they remain subject to comment in accordance with the agency’s good guidance practices. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-07-23/pdf/2021-15649.pdf?ref=fdaweb.com).

**Guide on Field Alert Reports**  
7/23/2021 *Federal Register* notice: FDA is making available a final guidance entitled *Field Alert Report Submission: Questions and Answers*. The document discusses the requirements for submission of field alert reports (FARs) by NDA and ANDA applicants, and it outlines recommendations for FAR submissions to help improve their consistency and relevancy. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-07-23/pdf/2021-15645.pdf?ref=fdaweb.com).

**Medical Product Communications Info Collection**  
7/22/2021 *Federal Register* notice: FDA has submitted to OMB an information collection extension entitled “Medical Product Communications That Are Consistent With the FDA-Required Labeling — Questions and Answers” (OMB Control Number 0910-0856). The collection supports agency guidance under the same title that includes recommendations that firms consider when developing “consistent with the FDA-required labeling (CFL)” presentations in their labeling and advertising materials to help ensure the presentations are not false or misleading. To view the notice, click [here](https://public-inspection.federalregister.gov/2021-15653.pdf?ref=fdaweb.com).